Lenalidomide Clonmel (Lenalidomide)

• Lenalidomide is an immunomodulatory agent used in hematologic malignancies and related disorders.
• Multiple Myeloma: improves progression‑free survival and overall response in patients with relapsed or refractory disease.
• Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and can induce cytogenetic remission.
• Mantle Cell Lymphoma: contributes to disease control when used in combination regimens.

• Lenalidomide binds to the cereblon component of the CRL4‑E3 ubiquitin ligase complex, altering substrate specificity and promoting degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). This results in modulation of cytokine production, inhibition of angiogenesis, and direct anti‑tumor activity through apoptosis and cell‑cycle arrest in malignant cells.

Lenalidomide may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Fatigue: persistent tiredness reported by many patients.
• Neutropenia: reduced neutrophil count increasing infection risk.
• Thrombocytopenia: lowered platelet levels that may cause bruising.
• Diarrhea: loose stools that may require supportive care.

Serious or Rare Side Effects

• Venous thromboembolism: deep vein thrombosis or pulmonary embolism.
• Severe neutropenia: profound immune suppression leading to serious infections.
• Secondary primary malignancies: emergence of new cancers.
• Hepatic toxicity: elevated liver enzymes or liver injury.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Cardiac events: arrhythmias or myocardial infarction in rare cases.

• Before initiating therapy, several safety considerations should be addressed.
• Pregnancy: contraindicated (Category X); avoid use in pregnant women.
• Thrombosis risk: assess patient history and consider prophylactic anticoagulation.
• Hematologic monitoring: perform regular complete blood counts to detect cytopenias.
• Renal impairment: evaluate kidney function and adjust dose if necessary.
• Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Lenalidomide can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce lenalidomide exposure.
• Anticoagulants (e.g., warfarin): increased risk of thromboembolic events when combined.
• Live vaccines: heightened risk of infection due to immunosuppression.
• Hormonal contraceptives: reduced efficacy; alternative contraception advised.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase drug levels.
• Immunosuppressants (e.g., cyclosporine, tacrolimus): additive infection risk.
• Other myelosuppressive agents (e.g., chemotherapy, azacitidine): may exacerbate bone‑marrow suppression.
• NSAIDs: potential for increased renal toxicity in susceptible patients.